Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting System
This study utilizes a transparent, reproducible analysis of the FDA Adverse Event Reporting System to confirm a class-wide disproportionate reporting signal for impaired gastric emptying across nine GLP-1 receptor agonist products, with semaglutide-based therapies showing the strongest signals, while emphasizing that these findings reflect reporting patterns rather than established clinical risk or causality.